E Fund Management Co. Ltd. Trims Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

E Fund Management Co. Ltd. trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 2.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,315 shares of the biopharmaceutical company’s stock after selling 569 shares during the period. E Fund Management Co. Ltd.’s holdings in Gilead Sciences were worth $1,646,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of GILD. Nilsine Partners LLC raised its holdings in shares of Gilead Sciences by 1.1% in the third quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock worth $891,000 after acquiring an additional 127 shares during the last quarter. Etesian Wealth Advisors Inc. raised its stake in Gilead Sciences by 0.7% in the 4th quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock valued at $1,486,000 after purchasing an additional 128 shares during the last quarter. Financial Counselors Inc. lifted its holdings in Gilead Sciences by 1.5% in the 4th quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock valued at $718,000 after purchasing an additional 128 shares in the last quarter. Revolve Wealth Partners LLC boosted its stake in shares of Gilead Sciences by 3.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 130 shares during the last quarter. Finally, Institutional & Family Asset Management LLC grew its holdings in shares of Gilead Sciences by 10.3% during the third quarter. Institutional & Family Asset Management LLC now owns 1,501 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 140 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.29% of the stock is currently owned by insiders.

Gilead Sciences Stock Down 0.5 %

NASDAQ:GILD traded down $0.34 during mid-day trading on Thursday, hitting $64.58. The company had a trading volume of 6,023,221 shares, compared to its average volume of 7,413,408. The business has a fifty day simple moving average of $70.09 and a 200-day simple moving average of $75.52. The firm has a market capitalization of $80.41 billion, a price-to-earnings ratio of 179.39, a PEG ratio of 1.31 and a beta of 0.22. Gilead Sciences, Inc. has a 1 year low of $64.33 and a 1 year high of $87.86. The company has a current ratio of 0.98, a quick ratio of 0.72 and a debt-to-equity ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating the consensus estimate of ($1.49) by $0.17. The business had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The company’s revenue was up 5.3% on a year-over-year basis. During the same period last year, the business posted $1.37 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 3.74 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 4.77%. The ex-dividend date of this dividend is Friday, June 14th. Gilead Sciences’s payout ratio is 855.56%.

Wall Street Analyst Weigh In

Several research firms have commented on GILD. Royal Bank of Canada lowered their target price on shares of Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating for the company in a research note on Friday, April 26th. Wells Fargo & Company reduced their target price on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research report on Monday, March 4th. Barclays lowered their price target on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a report on Monday, April 29th. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Finally, TD Cowen decreased their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Friday, April 26th. Eleven research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $83.69.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.